There are 2934 resources available
2442 - RNA expression profiles and splicing alterations in grade 1/2 neuroendocrine neoplasms from small intestine origin (siNENs). Final results of the GETNE-NETSEQ study
Presenter: Jaume Capdevila
Session: Proffered Paper – NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1796 - Malignant Non-adrenal Paraganglioma (mPara) and Adrenal Pheochromocytoma (mPheo) a Comparative Comprehensive Genomic Profiling (CGP) Study
Presenter: Gennady Bratslavsky
Session: Proffered Paper – NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
3410 - METEOR-1: A Phase I Study of GSK3326595, a First-In-Class Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Advanced Solid Tumors
Presenter: Lillian Siu
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
3777 - A first in human, phase 1 trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.
Presenter: Philippe Cassier
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1621 - Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in Combination with Pembrolizumab (PEM) in Patients (Pts) with Advanced/Metastatic (Adv/Met) Solid Tumors
Presenter: Aung Naing
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
441O - A Platform Trial with a Registry Study for Rare Cancers: MASTER KEY Project
Presenter: Shoko Narita
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
2651 - Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study
Presenter: Steffie Groenland
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1605 - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
Presenter: George Sledge
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
7184 - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Presenter: Dennis Slamon
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
1812 - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast